ELN2026 took place in Mannheim, Germany at March 3, 2026.
The MIRACLE Project Coordinators from Amsterdam UMC attended the European Leukemia Network (ELN) Annual Meeting. The ELN2026 meeting brings together leading experts in leukemia research and clinical care from across Europe.
Part of the ELN2026 agenda was the General Assembly of the RESOLVE consortium. During this meeting, Prof. Jacqueline Cloos (Amsterdam UMC) highlighted the MIRACLE project as part of her presentation.
The well attended ELN meeting itself provided an excellent opportunity to further share the goals and vision of the MIRACLE Marie Skłodowska-Curie Doctoral Network in an informal manner with the participants who are all working at the forefront of leukemia research.
MIRACLE focuses on understanding and targeting minimal residual disease (MRD). Through a multidisciplinary and intersectoral approach, the project combines single-cell multi-omics technologies, artificial intelligence, and innovative preclinical models, while training a new generation of researchers dedicated to combating leukemia relapse.
Participation in the ELN meeting, including the RESOLVE General Assembly strengthened connections with the European leukemia research community and created valuable opportunities for future knowledge exchange and dissemination of the MIRACLE project outcomes.
We thank the ELN2026 organizer, Prof. R Hehlmann, for the inspiring discussions and look forward to continued participation.
About the European Leukemia Network (ELN)
The European Leukemia Network (ELN) is a collaborative network of leading leukemia researchers and clinicians across Europe working together to improve the diagnosis, treatment, and outcomes of leukemia patients. Through international collaboration, ELN develops clinical guidelines, promotes research, and provides a platform for sharing the latest advances in leukemia science and care.
About the RESOLVE Consortium
RESOLVE is a European research initiative focused on improving the understanding and treatment of leukemia by studying therapy resistance and disease relapse. The consortium brings together leading researchers, clinicians, and institutions across Europe to develop innovative strategies that target residual leukemia cells and ultimately improve outcomes for patients.